For a decade, each new projection for drug sales from analyst group Evaluate has been higher than the last as new blockbusters and price hikes have pushed up its forecasts. Not this year.
For the first time since it has been publishing its World Preview reports, the life science commercial intelligence firm has lowered its forecast for industrywide drug sales, based largely on new attention to pricing.
